Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals (EGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Eagle Pharmaceuticals 50 TICE BOULEVARD SUITE 315 WOODCLIFF LAKE NJ 07677 USA

www.eagleus.com P: 201-326-5300

Description:

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.

Key Statistics

Overview:

Market Capitalization, $K 12,338
Enterprise Value, $K 19,488
Shares Outstanding, K 12,987
Annual Sales, $ 316,610 K
Annual Net Income, $ 35,640 K
Last Quarter Sales, $ 64,650 K
Last Quarter Net Income, $ 5,160 K
EBIT, $ 41,000 K
EBITDA, $ 54,740 K
60-Month Beta 0.62
% of Insider Shareholders 28.90%
% of Institutional Shareholders 85.36%
Float, K 9,234
% Float 71.10%
Short Volume Ratio 0.33

Growth:

1-Year Return -89.44%
3-Year Return -98.02%
5-Year Return -98.38%
5-Year Revenue Growth 33.75%
5-Year Earnings Growth -18.99%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 10/01/24
Earnings Per Share ttm 1.18
EPS Growth vs. Prev Qtr -11.36%
EPS Growth vs. Prev Year -48.30%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

EGRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 11.26%
Debt/Equity 0.28
Price/Sales 0.11
Price/Cash Flow 0.24
Price/Book 0.05
Book Value/Share 19.25
Interest Coverage 16.17
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar